๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 36 Beijing 20 Guangzhou 11 Tianjin 11 Jinan 6
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai36 Beijing20 Guangzhou11 Tianjin11 Jinan6
All 24 locations
Target enrolment
to

Trials with a site in Beijing

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
NCT07497386Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
150
Beijing
2026-04-28
Recruiting
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
NCT07241416Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
206
Beijing
2025-12-05
Recruiting
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
NCT07238283First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
662
Beijing
2025-12-02
Recruiting
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
NCT07140393Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
120
Beijing
2025-10-28
Not yet open
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis
NCT07102888Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
20
Beijing
2025-08
Not yet open
Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients
NCT07056439PET Imaging in Patients With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
50
Beijing
2025-07
Recruiting
A Trial of HRS-6768 in Patients With Advanced Solid Tumors
NCT06925581Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
84
Beijing, Shanghai
2025-04-24
Recruiting
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia
NCT06841731Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
100
Beijing
2025-04-03
Not yet open
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
NCT06731829For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
78
Beijing
2024-12
Recruiting
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
NCT06598735Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
290
Beijing
2024-11-05
Not yet open
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
NCT06368167Follicular Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
105
Beijing
2024-04
Recruiting
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
NCT06122389Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
130
Beijing
2024-02-05
Recruiting
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
NCT06015048HER2-expressing Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
364
Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-08-11
Active, closed
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
NCT05814354Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
551
Beijing
2023-06-30
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
NCT04957550Psoriatic Arthritis
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
418
Beijing
2021-08-30
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2021-03-18
Recruiting
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
NCT04342910Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
550
Beijing
2020-09-21
Recruiting
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
NCT04316364Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Active, closed
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
NCT03603951Relapsed or Refractory Mature Lymphoid Neoplasms
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
272
Beijing
2018-08-14
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

12 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 20 studies
PhaseStudiesRecruitingShare
Phase 38540%
Phase 25225%
Phase 1/24320%
Phase 13215%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Jiangsu HengRui Medicine Co., Ltd.2012
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.